Current gene therapy · 2026
Efficacy and Safety of Immune Checkpoint Inhibitors for Recurrent or Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis.
СтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yuanyuan, Wang Songyi, Mai Yirui, You Zhixi, Wang Yu, Wang Jiake, Lei Ye
Аннотация
BACKGROUND: Cervical cancer is a major global health challenge and requires the exploration of novel treatment strategies. Immune checkpoint inhibitors, particularly those targeting Programmed Death 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1), have emerged as promising therapeutic agents in oncology. This study aimed to evaluate the efficacy and safety of these inhibitors in the treatment of cervical cancer.
METHODS: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, Scopus, the Cochrane Library, and the China National Knowledge Infrastructure to identify studies published up to November 1, 2024. A total of 26 relevant studies were included, including 21 Non-Randomized Controlled Trials (Non-RCTs) and 5 Randomized Controlled Trials (RCTs). The analysis primarily evaluated the efficacy and safety of PD-1/PD-L1 inhibitors in patients with advanced cervical cancer. The primary outcomes included the objective response rate, disease control rate, progression-free survival, overall survival, and adverse events. Non-RCTs and RCTs were evaluated using ROBINS-I and ROB 2, respectively. Data analysis and visualization were performed using STATA 17.0 and GraphPad. This study has been registered with PROSPERO (registration number CRD42024510357).
RESULTS: Therapeutic outcomes indicated that the objective response rate in patients with cervical cancer was 44.30% (95% CI 31.06%-57.93%), and the disease control rate was 63.05% (95% CI 51.67%-73.78%). The complete response, partial response, stable disease, and progressive disease rates were 12.58% (95% CI 6.46%-20.13%), 26.87% (95% CI 19.92%-34.40%), 17.95% (95% CI 12.50%-24.07%), and 27.61% (95% CI 17.68%-38.71%), respectively. The median PFS was 6.22 months (95% CI 3.86-8.59), with 6- and 12-month PFS rates of 58.93% (95% CI 47.78%-69.65%) and 45.20% (95% CI 32.73%-57.96%), respectively. The median OS was 14.81 months (95% CI 8.45-21.16), with 6- and 12-month OS rates of 86.57% (95% CI 80.92%-91.42%) and 70.34% (95% CI 61.47%-78.53%), respectively. Regarding safety, the incidence of treatment-related adverse events was 83.24% (95% CI 73.93%-90.94%), serious adverse events was 25.71% (95% CI 15.33%-37.58%), adverse drug reactions was 71.57% (95% CI 57.61%-83.78%), and immunerelated adverse events was 34.26% (95% CI 27.11%-41.76%). Common treatment-related adverse events included anemia, diarrhea, nausea, and leukopenia.
CONCLUSION: The findings indicate that immune checkpoint inhibitors represent a potentially effective treatment option for patients with cervical cancer; however, their safety profile warrants careful consideration. Combination therapies involving PD-1 inhibitors appear to improve efficacy while maintaining manageable safety.
METHODS: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, Scopus, the Cochrane Library, and the China National Knowledge Infrastructure to identify studies published up to November 1, 2024. A total of 26 relevant studies were included, including 21 Non-Randomized Controlled Trials (Non-RCTs) and 5 Randomized Controlled Trials (RCTs). The analysis primarily evaluated the efficacy and safety of PD-1/PD-L1 inhibitors in patients with advanced cervical cancer. The primary outcomes included the objective response rate, disease control rate, progression-free survival, overall survival, and adverse events. Non-RCTs and RCTs were evaluated using ROBINS-I and ROB 2, respectively. Data analysis and visualization were performed using STATA 17.0 and GraphPad. This study has been registered with PROSPERO (registration number CRD42024510357).
RESULTS: Therapeutic outcomes indicated that the objective response rate in patients with cervical cancer was 44.30% (95% CI 31.06%-57.93%), and the disease control rate was 63.05% (95% CI 51.67%-73.78%). The complete response, partial response, stable disease, and progressive disease rates were 12.58% (95% CI 6.46%-20.13%), 26.87% (95% CI 19.92%-34.40%), 17.95% (95% CI 12.50%-24.07%), and 27.61% (95% CI 17.68%-38.71%), respectively. The median PFS was 6.22 months (95% CI 3.86-8.59), with 6- and 12-month PFS rates of 58.93% (95% CI 47.78%-69.65%) and 45.20% (95% CI 32.73%-57.96%), respectively. The median OS was 14.81 months (95% CI 8.45-21.16), with 6- and 12-month OS rates of 86.57% (95% CI 80.92%-91.42%) and 70.34% (95% CI 61.47%-78.53%), respectively. Regarding safety, the incidence of treatment-related adverse events was 83.24% (95% CI 73.93%-90.94%), serious adverse events was 25.71% (95% CI 15.33%-37.58%), adverse drug reactions was 71.57% (95% CI 57.61%-83.78%), and immunerelated adverse events was 34.26% (95% CI 27.11%-41.76%). Common treatment-related adverse events included anemia, diarrhea, nausea, and leukopenia.
CONCLUSION: The findings indicate that immune checkpoint inhibitors represent a potentially effective treatment option for patients with cervical cancer; however, their safety profile warrants careful consideration. Combination therapies involving PD-1 inhibitors appear to improve efficacy while maintaining manageable safety.